RBC Capital points out that notes released by the European Medicines Agency’s CHMP indicated that Biohaven (BHVN) had withdrawn the application for troriluzole in spinocerebellar ataxia. Investor sentiment has been…
Κωνσταντίνος Κουτουλάκης26/04/2025